"Antipsychotic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
| Descriptor ID |
D014150
|
| MeSH Number(s) |
D27.505.696.277.950.040 D27.505.954.427.210.950.040 D27.505.954.427.700.872.331
|
| Concept/Terms |
Antipsychotic Agents- Antipsychotic Agents
- Agents, Antipsychotic
- Antipsychotics
- Major Tranquilizers
- Tranquilizers, Major
- Tranquillizing Agents, Major
- Agents, Major Tranquillizing
- Major Tranquillizing Agents
- Neuroleptic Drugs
- Drugs, Neuroleptic
- Neuroleptics
- Tranquilizing Agents, Major
- Agents, Major Tranquilizing
- Major Tranquilizing Agents
- Antipsychotic Drugs
- Drugs, Antipsychotic
- Neuroleptic Agents
- Agents, Neuroleptic
Antipsychotic Effect- Antipsychotic Effect
- Effect, Antipsychotic
- Antipsychotic Effects
- Effects, Antipsychotic
|
Below are MeSH descriptors whose meaning is more general than "Antipsychotic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antipsychotic Agents".
This graph shows the total number of publications written about "Antipsychotic Agents" by people in this website by year, and whether "Antipsychotic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 1 | 3 | 4 |
| 1998 | 1 | 3 | 4 |
| 1999 | 1 | 2 | 3 |
| 2000 | 1 | 2 | 3 |
| 2001 | 4 | 2 | 6 |
| 2002 | 4 | 0 | 4 |
| 2003 | 3 | 2 | 5 |
| 2004 | 6 | 4 | 10 |
| 2005 | 10 | 3 | 13 |
| 2006 | 5 | 2 | 7 |
| 2007 | 7 | 4 | 11 |
| 2008 | 12 | 4 | 16 |
| 2009 | 11 | 2 | 13 |
| 2010 | 14 | 10 | 24 |
| 2011 | 10 | 3 | 13 |
| 2012 | 8 | 4 | 12 |
| 2013 | 13 | 9 | 22 |
| 2014 | 9 | 3 | 12 |
| 2015 | 10 | 6 | 16 |
| 2016 | 6 | 2 | 8 |
| 2017 | 10 | 9 | 19 |
| 2018 | 4 | 5 | 9 |
| 2019 | 9 | 1 | 10 |
| 2020 | 5 | 6 | 11 |
| 2021 | 3 | 0 | 3 |
| 2022 | 4 | 0 | 4 |
| 2023 | 13 | 0 | 13 |
| 2024 | 9 | 1 | 10 |
| 2025 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antipsychotic Agents" by people in Profiles.
-
Hyperleptinemia contributes to antipsychotic drug-associated obesity and metabolic disorders. Sci Transl Med. 2023 11 22; 15(723):eade8460.
-
Psychotropic Medication Prescribing: Youth in Foster Care Compared with Other Medicaid Enrollees. J Child Adolesc Psychopharmacol. 2023 05; 33(4):149-155.
-
History of Suicide Attempt and Clozapine Treatment in Veterans With Schizophrenia or Schizoaffective Disorder. Prim Care Companion CNS Disord. 2022 Nov 01; 24(6).
-
A Dilute and Shoot LC-MS/MS Method for Antipsychotics in Urine. J Anal Toxicol. 2020 May 18; 44(4):331-338.
-
Sex Differences in Body Mass Index and Obesity in Chinese Patients With Chronic Schizophrenia. J Clin Psychopharmacol. 2016 12; 36(6):643-648.
-
Association of the BDNF Val66Met polymorphism with BMI in chronic schizophrenic patients and healthy controls. Int Clin Psychopharmacol. 2016 11; 31(6):353-7.
-
Altered serum levels of interleukin-3 in first-episode drug-naive and chronic medicated schizophrenia. Schizophr Res. 2016 10; 176(2-3):196-200.
-
BDNF polymorphisms are associated with schizophrenia onset and positive symptoms. Schizophr Res. 2016 Jan; 170(1):41-7.
-
Increased interleukin-2 serum levels were associated with psychopathological symptoms and cognitive deficits in treatment-resistant schizophrenia. Schizophr Res. 2015 Dec; 169(1-3):16-21.
-
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. Can J Psychiatry. 2015 Oct; 60(10):441-50.